[Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].
A 51-year-old female patient died of Budd-Chiari syndrome during treatment with adjuvant DTIC mono-chemotherapy for malignant melanoma. We report on clinical course and laboratory findings in detail. Differentiating BCS from VOD, we describe the liver damages referring to the latest findings about the effect of DTIC in fibrinolysis. In order to prevent further lethal complications, we suggest to regard pre-existing liver damage as a contra-indication for DTIC therapy; to prefer intraspinal anesthesia for malignant melanoma of the lower extremities; to avoid hepatotoxic drugs and alcohol during chemotherapy; to protect DTIC from light; to extend the interval between first and second cycle. Laboratory data, the "finger-prints" of DTIC, are unreliable. Great attention should be paid to clinical findings which may justify immediate and high dose corticosteroid therapy as well as intensive care monitoring.
D006502:Budd-Chiari Syndrome / Q000139:chemically induced* / Q000401:mortality / Q000517:prevention & control; D003606:Dacarbazine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy*
D003606:Dacarbazine
Budd-Chiari-Syndrom nach Dacarbacin-(DTIC-)Therapie bei malignem Melanom--Ein vermeidbarer Zwischenfall?